SITE015-0184

SITE015 (POL) › SITE015-0184

SITE015-0184

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-04-12

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 130); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 90); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 70); relationship: not assessed

mild assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 68); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 43); relationship: NOT RELATED

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 3); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.